Compare PRAX & MTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | MTH |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.7B |
| IPO Year | 2020 | 1997 |
| Metric | PRAX | MTH |
|---|---|---|
| Price | $305.51 | $72.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $572.13 | $77.63 |
| AVG Volume (30 Days) | 329.6K | ★ 886.3K |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.87% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.18 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7,758.26 | $9.81 |
| P/E Ratio | ★ N/A | $85.61 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.25 | $58.03 |
| 52 Week High | $366.52 | $85.38 |
| Indicator | PRAX | MTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 42.86 |
| Support Level | $284.87 | $64.62 |
| Resistance Level | $331.21 | $71.13 |
| Average True Range (ATR) | 16.88 | 3.01 |
| MACD | -2.16 | -0.49 |
| Stochastic Oscillator | 34.34 | 20.44 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising twelve states: Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the Homebuilding segment.